These results demonstrate that the blood NK1 subset in patients with AD is at the late stage of NK cell development and key TFs including TBX21, NFATC2, and SMAD3 may play a vital role in this subset expansion. The gene discussed is SMAD3; the disease is Alzheimer disease.